



or a pharmaceutically acceptable salt thereof

ପ୍ରକାଶକ ମେଳିକା

Figure 1A



or a pharmaceutically acceptable salt thereof

Figure 1B





Figure 1C






Figure 1D



or a pharmaceutically acceptable salt thereof
R₁ and R₃ are the same and are:

Figure 1E




I

or pharmaceutically acceptable salt thereof

2025 RELEASE UNDER E.O. 14176

Figure 1F



or pharmaceutically acceptable salt thereof,

III,

or

I

Figure 1G




Figure 1H







Figure 1H (continued)



10153




10151




10150

MnTDE-2,5,IP



10201

MnTBAP



10158

MnTDP-2,5-IP

Figure 1H (continued)



Figure 2A

B16 Melanoma tumor - SOD mimetic treatment






Figure 2B




Figure 2C

Effect of Radiation & A EOL 10113 on Mammary Adenocarcinoma






Figure 3

Tumor Growth Inhibition
R3230 AC Mammary Adenocarcinoma in Fisher rats




Figure 4

Tumor growth inhibition (s.q. chambers)
Dose = 6 mg/kg








Figure 5
Tumor Angiogenesis
Dose = 6 mg/kg





Catalytic Antioxidant Metalloporphyrin
[MnTBAP]

Figure 6



Figure 7






Figure 8






Figure 9A







Figure 9B





JUL 29 2001
PATENT & TRADEMA



Figure 10A



Figure 10E



Figure 10B



Figure 10F



Figure 10C



Figure 10G




Figure 10D



Figure 10H



Figure 11





Figure 12



O I P E
JUL 29 2002
PATENT & TRADEMARK OFFICE
1935

Figure 13A




Figure 13B




Figure 14




Figure 15




Figure 16

A549 3H-Thymidine uptake at 24 hours




Figure 17A

Paraquat-Induced Injury of
Human A549 Cells (48 hr)




Figure 17B

Effect of MnTBAP on
Paraquat-Induced A549 Cell Injury






Figure 17C




Figure 17D






Figure 17E

Effect of ZnTMPyP on Paraquat-Induced A549 Cell Injury






Figure 18




Figure 19

Percentage of Study Days with Ulceration as
Indicated by a Score of 3 or Greater

